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In recent years, the concept of nutrition in patients with tumour diseases has been changing
very signiﬁcantly. The article discusses the pathogenesis of tumour cachexia and sarcopenia,
which have been intensively studied, particularly in the last ten years. The possibilities and
modern approaches in nutritional support in oncology are reviewed with a special emphasis
on  the group of elderly patients. Also, a detailed list of the most frequently used pharma-
conutrients in oncology is presented. The recommendations for nutritional care of elderlyKeywords:
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Tumour cachexia
Sarcopenia
Pharmaconutrients
oncological patients are given and discussed.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
pain. From this aspect, the perspective of an experienced clini-
cian is one of the most important factors in deciding when and1.  Background
In recent years, the concept of nutrition in patients with
tumour diseases has been very signiﬁcantly changed both
in terms of extended theoretical knowledge in this ﬁeld and
from the standpoint of practical use of nutritional support.1,2
This change stems from both a more  profound understand-
ing of the mechanisms and clinical consequences of tumour
cachexia and the practical availability of new nutritional
preparations based on the principles of nutritional pharma-
cology. Great progress has been made also in the speciﬁcation
of indications for nutritional support in patients with differ-
ent types of malignant tumours, as well as in the indications
based on the stage of development of the disease.
∗ Corresponding author at: Department of Research and Developmen
Králové, Czech Republic. Tel.: +420 495 832 166; fax: +420 495 834 841.
E-mail address: zadak@fnhk.cz (Z. Zadák).
1507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Publish
http://dx.doi.org/10.1016/j.rpor.2012.10.008Although in many  cases the convincing arguments are
based on the principles of evidence-based medicine (EBM),
which conﬁrm that nutritional support improves both mor-
bidity and mortality,3 it is often the case that an improvement
in the quality of life is of greater importance than the length of
a patient’s survival. One of the main principles is to maintain
the state of nutrition and particularly to decelerate the devel-
opment of sarcopenia, because from the viewpoint of medical
ethics, grave cachexia, with its associated shattering feeling
of exhaustion, belongs to the same category of nociceptive
stimuli as suffocation, death by thirst, and visceral or somatict, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec
by what means nutritional support of the oncological patient
is to be started.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Unfortunately, even amongst oncologists there still exist
utdated opinions that nutritional support does not sig-
iﬁcantly contribute to the therapeutic arsenal of care for
ncological patients, and even that it can be harmful. This
utdated approach stems from the lack of understanding of
ppropriate procedures of nutritional support in oncology, and
lso from the lack of knowledge of the latest methods and
ossibilities of pharmaconutrition (nutritional pharmacology)
nd the possibilities of organ-speciﬁc nutrition.
Nutritional support, in particular organ-speciﬁc nutrition
imed at the gut function maintenance regimen, is of major
mportance also for the maintenance of the intestinal barrier
n patients treated with chemotherapy or actinotherapy. The
ollapse of the intestinal barrier in the course of treatment of
he oncological patient usually has detrimental consequences
or the progress of the disease as well as its whole prog-
osis. Translocation of endotoxin and possible subsequent
ranslocation of living microorganisms to the blood circula-
ion system can be a lethal mechanism which can determine
he fate of the patient even in the case of an otherwise quite
ood prognosis based on intensive therapy of the tumour.
eglect of care for the intestinal barrier by providing precisely
anaged nutritional support using organ-speciﬁc prepara-
ions always creates great risk for the patient. The course and
onsequences of translocation of endotoxin from the intesti-
al lumen and eventually living organisms into the mesenteric
ymphatic nodes and the blood circulation system may not
how dramatic symptoms in the ﬁrst stage, particularly in
mmunosuppressed patients and patients undergoing inten-
ive chemotherapy.4,5
Metabolic stress (hypermetabolism, protein catabolism
ith development of SIRS and non-perforative sepsis from
he intestinal tract) often takes place in a very latent manner,
nd is a frequently overlooked mechanism which prematurely
ills the patient with tumour disease. In addition, the complex
f changes consequent to damage of the intestinal barrier in
he oncological patient is potentiated by any surgical interven-
ion in the abdominal cavity, which is usually associated with
ypoperfusion of the mesenteric bed, subsequent reperfusion
f the intestine and nutritional deﬁcit.
Progressive deterioration of the nutritional status is a typ-
cal manifestation of tumour disease, and the frequently
resent anorexia connected with a limited intake of food
esults in profound metabolic changes: increased proteolysis
nd lipolysis, decreased sensitivity to insulin, hypoalbumine-
ia  connected with disorders in the balance of minerals,
wellings and marked sarcopenia with a functional limita-
ion of muscle activity. A decrease in musculature, which in
ntensiﬁed tumour catabolism amounts to hundreds of grams
f muscle mass a day, weakening of the respiratory muscles,
nd immunosuppression due to hunger markedly participate
n the syndrome of tumour cachexia and the resulting compli-
ations, such as pulmonary infections. These changes result
n the premature death of patients who  are otherwise curable
rom the oncological aspect and have favourable prognoses.
Another consequence of tumour cachexia is increased
hemo- and radiotoxicity, which often causes interruption
f planned oncological treatment, and probably signiﬁcantly
ontributes to higher mortality.6–9 Of great importance for
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provision of nutritional support to oncological patients
before full development or even commencement of refrac-
tory tumour cachexia. This is evidenced in numerous papers
based on the latest and very exact studies.10–13 These latest
papers clearly demonstrate that nutritional support is one of
the important factors which improve tolerance to aggressive
oncological treatment, improve the quality of life and decrease
mortality. The precondition is that nutritional support is based
on correct indication, is not started late in the advanced or
terminal state, and also, especially, is based on the use of new
preparations which make use of nutritional pharmacology and
speciﬁc nutrients in pharmacological doses, with proper and
appropriate technique of administration (enteral nutrition,
parenteral nutrition, combined and transient type of nutri-
tion). There are great prospects in oncology for the application
of anaplerotic nutritional substrates.
2. Pathogenesis  of  tumour  cachexia
Pathogenesis of tumour cachexia has been intensively studied
particularly in the last ten years. According to the latest knowl-
edge, a pivotal role in the pathogenesis of tumour cachexia is
played by the inﬂammatory reaction, with its extraordinar-
ily rapid drawing on the energy of fat stores and devastation
of muscles. The inﬂammatory reaction is systemic in nature,
with interaction between the tumour and the host organ-
ism. An example is sensitivity to insulin and the circulating
levels of cholesterol, which are under the regulation of the
central nervous system and governed by humoral agents.
From this aspect, food intake is controlled from the area of
the hypothalamus and nucleus arcuatus, where orexigenic
and anorexigenic neurons are located. A group of neurons
in the nucleus arcuatus controls the production of polypep-
tides – pro-opiomelanocortins – which are subsequently cleft
into active hormones, melanocortins. Among them, the alpha-
melanocyte stimulating hormone mediates the anorexigenic
response by the route of melanocortins MC4. Functional inte-
gration of neuropeptide Y and pro-opiomelanocortin is closely
connected with food intake. This mechanism is also sup-
ported by demonstrations that neuropeptide Y participates
in the expression of “agouti-related protein”, which is the
natural antagonist of the melanocortin receptor MC4.14 In
the presence of a proliferating tumour the physiological bal-
ance between neuropeptide Y and pro-opiomelanocortin is
changed and the nucleus arcuatus is adjusted for anorexigenic
action, which is sensitive to the signals connected with the
metabolic situation in the peripheral tissues. These signals
include also an increase in proinﬂammatory cytokines pro-
duced by the growing tumour tissue, and the reaction of the
surrounding tissue to this proliferation. The hypothalamus is
informed about the presence of the tumour growing in the
periphery even in the situation when the tumour size amounts
to a few millimetres.7 Demonstrations for this phenomenon
are based on the knowledge that information on the inﬂam-
matory reaction originating from the action of the growing
tumour is relayed by the vagus afferent routes to the hypo-
thalamus, which generates a stress response by activation of
pro-opiomelanocortin neurons and inhibition of neuropeptide
Y neurons.
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Table 1 – Occurrence of malnutrition and increased rest energy expense (REE).
Type and localization of the tumour Degree of malnutrition REE > 110% norms
Gastric carcinoma 83% 45%
Small-cell lung carcinoma 60% 100%
Bronchogenic lung carcinoma 66% 100%
Breast carcinoma 36% ?
Large intestine carcinoma 54% 30%
Rectal carcinoma 40% 30%
Esophageal carcinoma 79% ?
Sarcoma 39–66% 100%
Pancreatic carcinoma 83%  ?
tracted decrease in energy supply and protein availability
in food results in the deterioration of cellular and organ
functions. This leads to markedly increased morbidity and
Table 2 – Comparison of metabolism and nutrition in
starving and tumour disease.
Category Starving Tumour disease
Absence of appetite Yes Yes
Weight ↓ ↓
Rest energy expense ↓ ↑
Blood glucose ↓ ±
Blood lactate ± ↑
Serum insulin ↓ ±
Plasma glucagon ↑ ±
Total plasma amino acids ↓ ↓
Excretion of nitrogen in urine ↓ ±
Glucose tolerance ↓ ↓
Whole-body glucose turnover ↓ ↑
Recycling of whole-body
glucose (%)
↑  ±
Recycling of whole-body
glucose degree
±  ↑
Whole-body protein turnover ↓ ±
Whole-body protein
synthesis
↓  ±
Whole-body protein
catabolism
±  Unknown
Gluconeogenesis from
alanine
↑  ↑
Plasma alanine ↓
Release of alanine from
muscle
↑  ↓
Release of glutamine ±
Intake of BCAA ↑Other solid carcinomas
With permission, Bozzetti, F.(19).
The reaction to the acute inﬂammatory response is char-
acterized by the total picture of the disease, which includes
loss of weight, anorexia, as well as anti-inﬂammatory reac-
tions caused by vagal mechanisms. This picture also includes
the reaction to suppress the inﬂammation and the related
immune response. In several recent years, new data have
appeared which elucidate the role of the hypothalamus in the
energy balance. The strong relationship between the hypo-
thalamus and total energy balance of the organism both in
the physiological and pathological situations, in particular
in relation to body weight, includes also a neuroregulatory
component.15–18
3.  Sarcopenia  and  tumour  cachexia
As suggested by its name, sarcopenia is characterized by a loss
of the muscle mass, which is physiological in the course of
ageing, but becomes a pathological phenomenon in some clin-
ical conditions such as grave catabolism and tumour cachexia
in oncological patients, in acute conditions connected with
infection (sepsis), after serious operations, and in polytrauma.
At present, the loss of muscle mass can be relatively well
quantiﬁed by means of dual x-ray absorptiometry (DEXA),
computer tomography, bioimpedance, biochemical methods,
and most simply, by anthropometric methods. The develop-
ment of sarcopenia is connected with a signiﬁcant decrease in
muscle strength and long-term muscle performance. In seri-
ous pathological sarcopenia, these functional manifestations
are associated with a feeling of extraordinary fatigue, even
up to an inability to secure the basal vital actions. Besides
this marked exhaustion, the development of sarcopenia is
inevitably connected also with a marked risk of injuries and
falls, and respiratory infections associated with the weakening
of the respiratory muscles and hypoventilation. The relation-
ship between the causes of sarcopenia and an increase in
morbidity and mortality is shown in Fig. 1.19
4.  Malnutrition  and  frequent  clinical
problems  in  oncological  patientsLongitudinal statistics from different research centres demon-
strate that tumour cachexia represents the main complicating
problem in oncological patients, at least in terms of preva-
lence. In some oncological patients, the decrease in body63%  75%
weight is one of the most frequent symptoms, reaching up
to 66% in the course of the oncological disease. A decrease
in body weight of more  than 10% of the pre-disease weight
occurs in 45% of adult oncological patients.20 The occurrence
of malnutrition is presented in Table 1. A survey of the most
frequent mechanisms and clinical consequences is shown in
Tables 2 and 3.
Malnutrition in oncological patients is the most frequent
cause of postoperative complications in this category. A pro-With permission, Bozzetti, F.(19).
↑, signiﬁcant increase; ↓, signiﬁcant decrease; ±, no change or with-
out signiﬁcant changes; BCAA amino acids with a branched chain.
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Result Physiology Triggers 
Oxidative stress 
↑ free radicals 
Ageing of cells 
Genetic 
changes 
Composition 
of the body 
Neuroendocrine 
regulation
Mortality 
Chronic diseases  
Tumours 
Anemia 
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Inflammation 
CRP 
IL-6 
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fFig. 1 – Relationship between the
ortality, as well as diminished response to chemotherapy.27
n increase in postoperative complications accompanies par-
icularly a decrease in body weight greater than 15%. This
alue is also characteristic of the development of immunosup-
ression and increased frequency of infectious complications,
ith their consequences for increased morbidity and mortal-
ty in oncological patients.
There is a close relationship between malnutrition and
ound healing. Degraded wound healing is particularly
vident during rapid development of protein-energy malnu-
rition, which closely correlates with a decrease in non-fat
ody mass, particularly a decrease below 10%. A num-
er of studies have demonstrated a relationship between
ound healing and a decrease in serum albumin, low trans-
errin levels (less than 1.5 g/l), or lymphopenia.21 Another
Table 3 – Deteriorated physiological functions in malnutrition.
Principal damage Mechanism 
Shifts in body ﬂuids Swelling
ECW  expansion, ↑ intersti
in lungs
Muscle strength ↑  fatigability 
Changes in contraction an
relaxation
Healing ↓ colloid osmotic pressure
↓ OH-proline deposition
Immunity insufﬁciency ↓ CD4, CD8 lymphocytes 
↓ cytokines secretion
↓ DHR
↓  blastic transformation
↓ bactericidal capacity of
neutrophils
↓ migration of lymphocyte
damage of function of neu
↓ adhesion and chemo tax
Hypothermia
With permission, Bozzetti, F.(19).ses of sarcopenia and mortality.
principal index which characterizes degraded healing is
decreased content of hydroxyproline in the healing tissue.
Subclinical deﬁcits of some vitamins and trace elements
(vitamin C, zinc, selenium) are the principal bioindicators of
degraded healing. An important role is played also by a deﬁcit
of some essential as well as non-essential amino acids such
as lysine, arginine, hydroxyproline and glutamine.
5. Possibilities  and  modern  approaches  in
nutritional  support  in  oncologyNutritional support serves as a means for the preserva-
tion of an acceptable quality of life, fewer complications
from the oncological disease, and an improvement in the
Clinical consequences
tial ﬂuid Disorder  in wound healing,
increased distribution space for
medicaments
Respiratory infection
d
 Dehiscence of sutures
Infection complications
s,
trophils
is
Mortality on hospitalization
nd radiotherapy 1 8 ( 2 0 1 3 ) 34–43
Table 4 – Speciﬁc pharmacological effect of amino acids.
Substrate Effect
Arginine Stimulation of immunity
Formation of NO
Thymotropic effect, antineoplastic effect
Glutamine Maintenance of intestinal barrier (toxins,
starving, radiation)
Substrate for cell division (mucosa, bone
marrow)38  reports of practical oncology a
conditions for chemo- and radiotherapy. In most cases, nutri-
tional support requires the use of special preparations based
on nutritional pharmacological formulae. According to the
recommendations of the European Society for Parenteral and
Enteral Nutrition (ESPEN), the use of conventional application
of parenteral or enteral nutrition or prolonged delay before
commencement of specialized nutritional support intended
for oncological patients can be considered a failure of proper
care for the patient. In countries with developed healthcare
systems, non-provision of nutritional support to the oncologi-
cal patient is considered to be an act of neglect. On the other
hand, it is necessary that the indication for nutritional support
is correct not only in its own right, but also from the stand-
point of individual selection of preparations and dosage. As
has already been mentioned, indication criteria must be taken
into consideration:
(1) type of tumour and the stage of development of the dis-
ease;
(2) age, sex and weight of the patient, and the resulting proper
dose of nutrients and energy, and the content of substrates
with nutritional pharmacological effect;
(3) all contraindications related to the syndrome of “over-
feeding”, the possibilities of speciﬁc organ support, and
the suitable route of administration (complete or supple-
mentary parenteral nutrition, peripheral or central type of
parenteral nutrition, puncture gastrojejunostomy, nasoje-
junal tube, or sipping).
The determination of nutritional support must be calcu-
lated precisely, and not just administered to the patient by
estimate; as a minimum, the MUST system (malnutrition
universal screening tool) must be employed.29 In unstable
patients with a less favourable reaction to the commence-
ment of nutritional support, the most suitable thing is, of
course, regular measurement of energy consumption and uti-
lization of individual energy substrates by means of indirect
energometry.29,30
As far as the route of administrations is concerned, in the
ﬁrst stage the most suitable one is sipping, and in the case
of considerable loss of appetite and vomiting it is the admin-
istration of pharmacologically prepared enteral nutrition via
a nasojejunal tube (the requirement of administration of liq-
uid nutrition behind the Treitz ligament should always be
respected to eliminate the risk of dilation of the abdomen,
vomiting, or aspiration). In the overwhelming number of
cases, proper dilution and administration of preparations
behind the Treitz ligament will achieve successful dispens-
ing of energy and a sufﬁcient variety of amino acids to
the catabolic patient with chronic type of tumour cachexia;
this will improve his/her reaction to pharmacotherapy and
actinotherapy.7 The decision is very sensitive in situations
where the patient will undergo surgery in the future, or where
the patient has reached an enhanced degree of malnutri-
tion. In the latter case, there is a risk that total parenteral
nutrition administered into the central vein may lead to
the development of infectious complications, in particular
the development of catheter sepsis, which in this type of
patient can have fatal consequences. For this reason, a well
considered decision about the type and composition of theBCAA + arginine Support and synthesis of proteins in
muscle and anabolism of host
administered artiﬁcial nutrition is the principal precondition
of its success and safe use. In most studies reporting unsatis-
factory outcomes of artiﬁcial nutrition in oncological patients,
a more  profound analysis reveals a whole series of errors and
ignorance in the use of the method. In these cases, artiﬁcial
nutrition, in particular that administered in the form of par-
enteral nutrition or puncture gastrojejunostomy, becomes a
treatment which endangers the patient, rather than a beneﬁt.
These opinions have also been formulated in the recent meta-
analyses of the European Society for Parenteral and Enteral
Nutrition (ESPEN). The decision algorithm for the administra-
tion of artiﬁcial nutrition to oncological patients is presented
in Fig. 2.
6.  Possible  pharmaconutrition  in  artiﬁcial
nutrition  in  oncological  patients
Amino acids – a list of the most frequently used pharmaconu-
trients in oncology is presented in Table 4.
Glutamine is undoubtedly one of the most frequently used
pharmaconutrients due to its favourable and efﬁcient effect
in immunity modulation and it’s securing of positive nitrogen
balance. It is also a nutrient which has been demonstrated
to ensure the integrity of the intestinal mucosa and thus the
functionality of the intestinal barrier (Fig. 3). This effect of
glutamine is of extraordinary importance, particularly in the
course of chemotherapy.5
Arginine is a nonessential amino acid, which, however,
under load, is not synthesized in sufﬁcient amount to the
endogenous metabolic pool, and which therefore must be sup-
plemented as a potentially essential nutrient. Enteral nutrition
enriched with arginine, RNA and omega-3 fatty acids is at
present at the centre of attention from the standpoint of artiﬁ-
cial nutrition of oncological patients. These enrichments aim
to boost the mechanisms of immunomodulations and sup-
press growth of the tumour, and thus improve morbidity and
mortality in oncological patients. In other supplements, these
types of speciﬁc nutritions are enriched with vitamin D,  E, C,
selenium and coenzyme Q.
Leucine is a hydrophobic neutral branched amino acid with
the properties of a branched amino acid, and is necessary
for the synthesis of proteins. At the same time, leucine is an
important source of energy, in particular for muscles. Oxida-
tion of leucine, as in other branched amino acids, requires
thiamine, riboﬂavin, pyridoxine, niacin, biotin, pantothenate,
ubiquinone, magnesium, and iron. An important property of
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 34–43 39
Abbreviations: B. W.  – body weight, PUFA – polyunsaturated fatty acids 
Active oncological treatment 
Diagnosis of tumour  
and evaluation of the state of 
nutrition 
Stable weight, 
good tolerance of therapy 
(loss of B. W.  < 10 %) 
No malnutrition 
No treatment, 
monitoring!!!
Malnutrition + active 
oncological treatment 
Deterioration of 
nutrition 
↓ bioindicators 
↓ T. H. > 10 % 
Specialized nutritional support, 
multimodal approach ( ω-3 
PUFA, leucine, glutamine, 
megestrol acetate, COX-2 
inhibitors, corticosteroids) 
Monitoring of nutrition, 
standard nutritional support 
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eucine is its capacity to provide energy even under critical
ondition, when glucose intolerance has developed and glu-
ose is oxidized with difﬁculty. It is also capable of replacing
atty acids as a source of energy, if under critical condition
nd hypoxia oxidation of fatty acids is blocked. Leucine is also
n important precursor in cholesterol synthesis, thus play-
ng an important role in the regeneration and reparation of
issues. Insufﬁciency of leucine in the muscles decreases the
roduction of cholesterol, which is necessary for the build-
ng of the membranes of muscle cells. For this reason and by
eans of this mechanism leucine very markedly inﬂuences
he intensity of sarcopenia31. Leucine gives rise to an impor-
ant metabolite beta-hydroxy-beta-methyl-butyrate (HMB), a
arked regulator in the anabolism of muscle tissue. Although
ydroxymethylbutyrate does not have such a marked effect on
sepsis, MODS, polytr
lungs 
glutamine 
bone marrow cell 
proliferation 
muscle
toxins
glutamine 
glutamine 
to
patology (ischemia, necrosis, toxin 
reparation and proliferation (evoked by higher
from stores and synthetic sites 
Fig. 3 – Role of glutamine inal support in oncology.
the synthesis of proteins in the muscle and on the suppression
of sarcopenia as does leucine, this metabolite is indispens-
able for the immune functions and for the regeneration of
damaged cells in all tissues of the human organism, includ-
ing those damaged by toxic medicaments and those required
for the maintenance of the structural and functional ability
of the muscle tissue (Fig. 4). In the muscle tissue, HMB  acts
by the mechanism of stabilization of the sarcolemma, and in
addition it suppresses proteolysis of muscle proteins. Since
maintenance of muscle tissue is dependent primarily on the
synthesis of cholesterol and other isoprenoids de novo, use is
made of HMB as a precursor in their synthesis, in particular
in situations of increased metabolic requirement. At present,
supplementation with HMB is recommended in the amount
of 3 grams a day in three divided doses.22
auma, ischemia 
bowel (bowel barrier 
impairment, endotoxin 
translocatio n)
glutamine 
xins
bowel 
reparation
alanine 
liver 
acute phase protein 
synthesis 
s)
 glutamine supply 
 the critical condition.
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Immunit y    Decreased morbidity Increased synthesis of cell     
cells                                  membranes                                  and mortality 
Muscle          Increased synthesis of Increased muscle 
        membranes cell mass and function
       Acetyl-CoA +              Citrate, ketonase, 
       Acetoacetyl-CoA         & acetate 
       HMB             KIC              Leucine     HMG-CoA 
CHOLESTEROL 
Chole sterol  synthesis  in  cytosol  
Immune 
respons e
Muscle  
damage 
Small or no utilization  of 
chol esterol in pe riph eral  
tissues 
Dietary HMB (increase d supply in 
increase d req uire men ts
MB  oFig. 4 – Effect of leucine and H
7.  Pleiomorphous  effect  of  polyunsaturated
omega-3  fatty  acids  in  pharmaconutrition  in
oncological  patients
Polyene omega-3 and omega-6 fatty acids are indispensable
fatty acids, which are not produced in the human body. In
addition, the ‘western type’ diet contains a low amount of
omega-3 fatty acids, so that the ratio omega-6 PUFA/omega-
3 PUFA is usually increased above the optimal value. The
human organism obtains the majority of the required amount
of omega-3 fatty acids from fat contained in ﬁsh and from
alpha-linolenic acid, contained in some plants and plant fruits
(nuts). Contemporary clinical studies demonstrate that an
increased supply of omega-3 fatty acids is capable of stabiliz-
ing body weight in patients suffering from the manifestations
of tumour cachexia. For this effect, however, the usually rec-
ommended doses of omega-3 fatty acids are insufﬁcient, and
pharmacological doses must be consumed, corresponding to
5–10 g of omega-3 fatty acids daily. The above-mentioned stud-
ies employed higher metabolites of linolenic acid, namely
eicosapentaenoic and docosahexaenoic acids. The prepara-
tions intended for the treatment of tumour cachexia currently
available on the market contain mostly a mixture of EPA and
DHA.23,24
Especially favourable effects have been observed with the
use of n-3 PUFA in oncological patients after extensive abdom-
inal surgery, where there appears to be a decreased occurrence
of infectious complications, and the immune response of the
patient is improved. Studies aimed at the effect of simul-
taneous therapy with anthracyclines in breast carcinoma
demonstrate that after higher doses of omega-3 fatty acids
the progression of the tumour is decelerated, toxicity of the
anthracyclines is decreased, and mortality is improved.25 The
potential mechanism by which omega-3 fatty acids modulate
the response to the tumour and improve tumour cachexia is
presented in Fig. 5. The total effect is multifactorial, but one
of the important mechanisms which explains the favourablen suppression of sarcopenia.
effect of omega-3 fatty acids in tumour cachexia is the sup-
pression of the inﬂammatory reaction. There exist papers
which demonstrate that the suppression of tumour cachexia
by the action of omega-3 fatty acids is closely connected with
the presence of the markers of inﬂammatory reaction.26
8.  Conclusions  and  recommendations
Recommendations of the European Society for Parenteral and
Enteral Nutrition (ESPEN) for oncological and transplanted
patients:
- Avoid prolonged preoperative fasting.
- Ensure a return to the normal dietary regimen after the
surgery as soon as possible.
- Without the manifestations of malnutrition commence
enteral nutrition in patients, where it is evident that they
will not receive food normally for a period longer than
7 days, if an operation follows (it holds true also in the
cases when the patient receives less than 60% of the rec-
ommended dose for a period longer than 10 days).
- It is recommended to postpone elective surgical interven-
tion for the purpose of preoperative enteral nutrition in
the oncological patient, if there is a marked nutrition risk
deﬁned by the presence of at least one of the following three
criteria:
(1) A decrease in body weight greater than 15% in 6 months.
(2) BMI lower than 18.5 kg/m2.
(3) Serum albumin lower than 30 g/l.For patients in nutrition risk, the nasojejunal tube is to be
introduced within 24 hour after surgery (recommendation
degree A).
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Commence nutritional support via a thin tube with a low
ﬂow (10–20 ml/hr particularly in expected worse tolerance
of nutrition).
Use enteral nutrition with speciﬁc substrates (arginine,
omega-3 fatty acids and nucleotides) perioperatively irre-
spective of nutrition risk in the following patients: major
surgery in an oncological disease in the area of the neck,
head (laryngectomy, pharyngectomy); in the case of a major
surgery of oncological character (esophagectomy, gastrec-
tomy, pancreatoduodenectomy).
Frequently, patients exposed to major gastrointestinal
urgery receive, simultaneously with enteral nutrition, large
olumes of crystalloids intravenously during and after the
urgery. A large liquid load can result in distension and
n increase in body weight of several kilograms. This phe-
omenon can be the main cause of postoperative ileus and
ecelerated emptying of the stomach, and that is why the
ube must be preferably introduced into the ﬁrst loop of the
ejunum. It prevents dilation of the stomach and the risk of
astric content aspiration.
Disproportionately low intake of energy in oncological
atients for a period longer than 14 days is connected with
igh mortality. Enteral nutrition support using a tube is thus
ndicated also in patients without manifest signs of malnutri-
ion, if such a prolonged period of insufﬁcient food intake is
xpected.27tabolism of the normal and tumour cell.
Conclusions from the guidelines of the European Society
for Parenteral and Enteral Nutrition (ESPEN) in nonsurgical
oncological patients 28,29:
- Parenteral nutrition is not recommended when the nutri-
tional condition of the oncological patient is good and the
food intake is not disturbed and is not expected to be so in
the future.
- Perioperative parenteral nutrition is strictly recommended
in malnutrition patients, where the food intake is disturbed
and enteral nutrition cannot be used. The beneﬁts greatly
exceed the risks.
- Routine parenteral nutrition, however, is not recommended
as a standard in well-nourished patients during nonsurgical
oncological treatment and in normal food intake, which must
be monitored quantitatively.
- Parenteral nutrition is recommended in patients with
untreatable malignant disease, if there is a rapid loss of body
weight and a markedly decreased intake of nutrients orally
or via a tube (supplementary parenteral nutrition).
Recommendations according to the ESPEN guidelines:- In hematooncological patients, parenteral nutrition is to be
reserved only for cases of grave mucositis, ileus, intractable
vomiting (recommendation degree A).
nd ra
r
1
1
1
1
1
1
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- An addition of glutamine to nutrition is suitable (recommen-
dation degree B).
- Total supply of energy per day in oncological patients is best
measured by means of indirect energometry, but it is pos-
sible to use the recommendation of 20–25 kcal/kg of body
weight per day in bedridden patients and 25–30 kcal/kg of
body weight per day for walking patients.
- According to preliminary meta-analyses, in patients in the
course of chemotherapy and actinotherapy it is suitable to
use speciﬁc pharmaconutrition preparations.
- The therapeutic contribution of parenteral nutrition in
oncological patients of a nonsurgical character is as fol-
lows: prevention and treatment of malnutrition (or tumour
cachexia); improvement of the tolerance of oncological
therapy; suppression of undesirable effects of oncological
therapy; improvement of the quality of life.7
- Hematooncological patients are less endangered by infec-
tious complications and impairment of the intestinal barrier
with the use of parenteral nutrition supplemented with glu-
tamine (recommendation degree B). Although the optimal
dose of glutamine in hematooncological patients has not yet
been exactly determined, according to the available stud-
ies a dose of approximately 0.6 g glutamine per kg of body
weight a day is recommended.
Use of pharmaconutrition with arginine, omega-3 fatty
acids, nucleotides and glutamine is indicated in the following
situations27:
- Tumours in the region of the head and neck even in good
nutritional condition (recommendation degree A).
- Extensive abdominal surgery – oesophagus, gastrectomy,
duodenopancreatectomy (recommendation degree A).
- Presence of malnutrition in the perioperative period.
Nutrition support is indicated in all oncological patients
suffering from marked malnutrition prior to major surgery,
for a period of at least 10–14 days prior to the surgery, even if
the surgery has to be postponed (recommendation degree A).
The criterion of malnutrition in this case is:
- Decrease in body weight > 10–15% within 6 months.
- BMI  < 18.5 kg/m2.
- Serum albumin < 30 g/l (in absence of liver or renal dysfunc-
tion).
Although there is a high probability that nutrients are used
also for the nutrition of the tumour tissue, the risk of increased
morbidity and mortality resulting from tumour cachexia pre-
vails over the clinical risk of the tumour’s using the nutrition
substrates for stimulation of its growth.Conﬂict  of  interest
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